Use of Biological Agents in Patients With Moderate to Severe Psoriasis
Authors:
Open Access
- 1 July 2007
- journal article
- editorial
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 143 (7) , 846-850
Abstract
Research from JAMA Dermatology — Use of Biological Agents in Patients With Moderate to Severe Psoriasis — A Cohort-Based PerspectiveKeywords
This publication has 11 references indexed in Scilit:
- Initial experience with routine administration of etanercept in psoriasisBritish Journal of Dermatology, 2006
- British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005British Journal of Dermatology, 2005
- High Levels of Ultraviolet B Exposure Increase the Risk of Non-Melanoma Skin Cancer in Psoralen and Ultraviolet A-Treated PatientsJournal of Investigative Dermatology, 2005
- Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque PsoriasisArchives of Dermatology, 2005
- Biological therapies in the systemic management of psoriasis: International Consensus ConferenceBritish Journal of Dermatology, 2004
- Advancements in the Treatment of Psoriasis: Role of Biologic AgentsJournal of Managed Care Pharmacy, 2004
- A Randomized Trial of Etanercept as Monotherapy for PsoriasisArchives of Dermatology, 2003
- An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque PsoriasisArchives of Dermatology, 2003
- Assessing the Safety of Immunologic Modifiers for the Treatment of Chronic Disease: the Psoriasis ParadigmJournal of Investigative Dermatology, 2003
- Oral Methoxsalen Photochemotherapy for The Treatment of Psoriasis: a Cooperative Clinical TrialJournal of Investigative Dermatology, 1977